Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6721667 | 0.90 | REN (0.54) | SLC6A2SLC6A4SLC6A3REN | |
| SCHEMBL6719840 | 0.88 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2HTR3A | |
| SCHEMBL12723100 | 0.88 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2HTR3A | |
| SCHEMBL1586771 | 0.86 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2MCHR1 | |
| Hydrochloric Acid SCHEMBL1587068 | 0.85 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2MCHR1 | |
| SCHEMBL6717253 | 0.81 | REN (0.53) | REN | |
| SCHEMBL6824940 | 0.80 | REN (0.54) | SLC6A2SLC6A4SLC6A3CYP2D6REN | |
| SCHEMBL6724579 | 0.80 | REN (0.54) | SLC6A2SLC6A4SLC6A3CYP2D6REN | |
| SCHEMBL6724371 | 0.80 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3MAOBCYP2D6 | |
| SCHEMBL6724774 | 0.80 | REN (0.56) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | claimed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | ALOX5 2214/4885SLC6A2 1310/4885SLC6A4 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.